Condition
Castrate-resistant Prostate Cancer (CRPC)
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
100.0%
3 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
3 of 0 completed with results
Key Signals
3 with results0
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Terminated3
Clinical Trials (3)
Showing 3 of 3 trials
NCT03690141Phase 2TerminatedPrimary
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
NCT01450683Phase 2Terminated
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
NCT01020305Phase 1Terminated
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Showing all 3 trials